Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer

Abstract

This study aimed to detect potential serum biomarkers for gastric cancer. In the present study, we used magnetic bead-based purification and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry to detect potential serum markers in 70 gastric cancer (GC) patients compared with 72 healthy controls. On average, up to 81 peaks, of which 11 were significantly different m/z peaks (fold change >1.5; P < 0.001, Wilcoxon rank sum test) between GC group and healthy controls were detected. Two potential gastric serum biomarkers (m/z values of 1546.02 and 5335.08), with higher and specific expression in GC patients were further identified as peptide regions of SERPINA1 and ENOSF1. Enzyme-linked immunosorbent assays (ELISAs) were used to analyze 210 additional serum samples obtained from 36 healthy volunteers, 36 GC patients, 30 GU patients, 36 nonsmall-cell lung cancer (NSCLC) patients, 36 clear-cell renal cell carcinoma (CCRCC) patients, and 36 pancreatic cancer patients to verify the expression of SERPINA1 and ENOSF1 in GC sera. The suitability of the present method for gastric serum proteomic analysis was demonstrated and led to the identification of two peptide regions and their corresponding proteins as potential serum biomarkers for the serum detection of GC.

The plasma peptides of ovarian cancer

“…Ovarian-cancer-specific peptides and/or phosphopeptides from cellular proteins, membrane proteins, nucleic acid binding proteins, signaling factors, metabolic enzymes and others including uncharacterized proteins showed significantly greater observation frequency. In agreement with the literature, peptides from many common proteins including acute phase response proteins such as Haptoglobin (HP) [39], Haptoglobin Related Protein (HPR), Alpha Anti Trypsin (SERPINA1) [15] and others were more frequently observed in ovarian cancer samples [38] (Table 1). The Chi Square analysis showed some proteins with χ 2 values that were apparently far too large (χ 2 ≥ 60, p < 0.0001, df 1) to all have resulted from random sampling error (Fig.…”

Serpin peptidase inhibitor clade&nbsp;A member&nbsp;1‑overexpression in gastric cancer promotes tumor progression <em>in&nbsp;vitro</em> and is associated with poor prognosis

“…High expression of SERPINA1 has been observed in prostate (55), lung (55) and colorectal (18) cancer. SERPINA1 was also reported to be upregulated in serum samples of patients with gastric cancer compared with healthy individuals (56). The present study demonstrated that SERPINA1 was overexpressed in colorectal, esophageal, gastric and pancreatic cancer, which indicated a strong association between a high SERPINA1 mRNA levels and digestive system tumorigenesis.…”

Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines

“…According to PANTHER Classification System, the protein encoded by SERPINA1 is a serine protease inhibitor involved in endopeptidase inhibitor activity, protease binding and serine-type endopeptidase activity. Higher levels of SERPINA1 has been associated with chemoresistance of human epithelial ovarian cancer [72] and breast cancer [73] and has also been proposed as a potential serum biomarker for GC [74]. However, the role of SERPINA1 in resistance to CDDP in GC has not been clarified yet.…”